Clinical Trial

Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of celecoxib combined with R-CHOP versus R-CHOP in the treatment of newly diagnosed advanced CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).The primary endpoint is Complete Response Rate (CRR)
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-23
notable Primary completion pushed: 2026-12-31 -> 2028-03-05 2026-07-23
minor Completion pushed: 2028-12-31 -> 2029-05-05 2026-07-23
Trial Details
NCT Number NCT07494565
Lead Sponsor Sun Yat-sen University
Conditions Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
Enrollment 60 participants
Start Date 2026-03-06
Primary Completion 2028-03-05 (estimated)
Study Completion 2029-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-22